More proof now in on hydroxychloroquine's effectiveness - still banned here, page-2 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by hersuit: ↑

https://pubmed.ncbi.nlm.nih.gov/34565108/

.2021 Sep 24;22(3):1063-1072.
doi: 10.31083/j.rcm2203116.
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
Matthieu Million¹, Jean-Christophe Lagier¹, Hervé Tissot-Dupont¹, Isabelle Ravaux¹, Catherine Dhiver¹, Christelle Tomei¹, Nadim Cassir¹, Léa Delorme², Sébastien Cortaredona², Sophie Amrane², Camille Aubry², Karim Bendamardji¹, Cyril Berenger², Barbara Doudier¹, Sophie Edouard¹, Marie Hocquart², Morgane Mailhe¹, Coralie Porcheto¹, Piseth Seng¹, Catherine Triquet¹, Stéphanie Gentile³, Elisabeth Jouve³, Audrey Giraud-Gatineau², Herve Chaudet², Laurence Camoin-Jau⁴, Philippe Colson¹, Philippe Gautret², Pierre-Edouard Fournier², Baptiste Maille⁵, Jean-Claude Deharo⁵, Paul Habert⁶, Jean-Yves Gaubert⁶, Alexis Jacquier⁶, Stéphane Honore⁷, Katell Guillon-Lorvellec¹, Yolande Obadia², Philippe Parola², Philippe Brouqui¹, Didier Raoult¹
Affiliations
PMID:34565108
DOI:10.31083/j.rcm2203116Free article

Abstract
We evaluated the age-specific mortality of unselected adult outpatients infected with SARS-CoV-2 treated early in a dedicated COVID-19 day hospital and we assessed whether the use of hydroxychloroquine (HCQ) + azithromycin (AZ) was associated with improved survival in this cohort. A retrospective monocentric cohort study was conducted in the day hospital of our center from March to December 2020 in adults with PCR-proven infection who were treated as outpatients with a standardized protocol. The primary endpoint was 6-week mortality, and secondary endpoints were transfer to the intensive care unit and hospitalization rate. Among 10,429 patients (median age, 45 [IQR 32-57] years; 5597 [53.7%] women), 16 died (0.15%). The infection fatality rate was 0.06% among the 8315 patients treated with HCQ+AZ. No deaths occurred among the 8414 patients younger than 60 years. Older age and male sex were associated with a higher risk of death, ICU transfer, and hospitalization. Treatment with HCQ+AZ (0.17 [0.06-0.48]) was associated with a lower risk of death, independently of age, sex and epidemic period. Meta-analysis evidenced consistency with 4 previous outpatient studies (32,124 patients-Odds ratio 0.31 [0.20-0.47], I²= 0%). Early ambulatory treatment of COVID-19 with HCQ+AZ as a standard of care is associated with very low mortality, and HCQ+AZ improve COVID-19 survival compared to other regimens.

Expand

Posted in PubMed 24th, withdrawn 29th.

Who knows what is correct any more ??

"WITHDRAWN: Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause."

https://www.sciencedirect.com/science/article/pii/S1201971221004689

"What are Withdrawn Articles in Press?

Withdrawn Articles in Press are proofs of articles which have been peer reviewed and initially accepted, but have since been withdrawn before being published in this publication.

Reasons for withdrawal may be a decision by the author and/or editor, accidental duplication of an article elsewhere, or because the content violates the Elsevier publishing policy in some way.

Withdrawn Articles in Press are only visible to users when following an external link, e.g., a PubMed or DOI link. Such Withdrawn Articles in Press are not searchable or otherwise available in ScienceDirect."